Analyst Research

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: New Constructs, LLC
$25.00
Provider: MacroRisk Analytics/EconomicInvestor
$25.00
Provider: ValuEngine, Inc.
$25.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Alexion Pharmaceuticals Inc Reaffirms FY 2012 Guidance-Conference Call


Monday, 7 Jan 2013 12:00pm EST 

Alexion Pharmaceuticals Inc raised fiscal 2012, it expects revenue of $1.120 to $1.130 billion and non-GAAP earnings per share (EPS) to be in the range of $1.99 to $2.04 per share. According to I/B/E/S Estimates, analysts on an average were expecting the Company to report revenues of $1.129 and EPS of $2.02 for fiscal 2012. 

Company Quote

168.22
1.75 +1.05%
22 Aug 2014